Literature DB >> 4186183

L-dopa for progressive supranuclear palsy.

R Jenkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4186183     DOI： 10.1016/s0140-6736(69)90449-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.

Authors:  A Neophytides; A N Lieberman; M Goldstein; G Gopinathan; M Leibowitz; J Bock; R Walker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

4.  Reversible supranuclear ophthalmoplegia associated with Parkinsonism.

Authors:  R J Guiloff; R J George; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-06       Impact factor: 10.154
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.